ImmunityBio, Inc. , a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation's largest independent providers of urology and related specialty services, is one of the ...

Aurobindo, that last year signed a deal with U.S. drugmaker MSD to manufacture one of their biologics products at its ...

Introduction Vaccines are biological preparations that stimulate the immune system to develop protection against specific infectious diseases.

Merck says the expansion in Durham is part of more than $12 billion the company has invested in U.S. manufacturing and ...

According to the company, the new, 225,000-square-foot expansion is a "crucial component" of a more than $12 billion infusion ...

At its sprawling complex in Durham, N.C., Merck has opened a new $1 billion, 225,000-square-foot manufacturing plant slated ...

New facility will manufacture HPV vaccines Gardasil and Gardasil 9. Merck plans to invest $8 billion more in U.S. by 2028. A ...

ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's ...

BACKGROUND Bacillus Calmette-Guérin (BCG) is one of the most successful vaccines in the world and evidence suggests it can be used as a bacterial vector to deliver heterologous antigens. OBJECTIVES We ...

Gene's lead asset shows high complete response rates in BCG-unresponsive NMIBC patients. Click here to read why ENGN stock is a Buy.

Merck, also known as MSD outside the U.S. and Canada, plans to significantly expand its workforce in India, aiming for around 2,700 employees by the year's end. The company focuses on therapy areas ...